R&D spending in Hungary increased 3.3% last year to HUF 245.7 billion ($1,483 million) to make up 0.97% of GDP, down from 1% in 2006. Private funding accounted for 44% of R&D expenditures, the government represented 44%, while foreign funding made up 11% and nonprofits represented 1%. Basic and applied research accounted for 16% of […]

China is the best outsourcing destination for pharmaceutical R&D and manufacturing in Asia, according to an analysis by PricewaterhouseCoopers (PwC). The results are based on an analysis of cost, risk and market opportunity, which were assigned the respective weights of 33%, 37% and 30%. The other top 5 destinations are India, Korea, Taiwan and Japan. […]

The Federal Ministry for Education and Research (BMBF) has selected three public-private consortia to receive €100 million ($142.9 million) to advance the efficiency of pharmaceutical research. The Max Planck Drug Discovery & Development Center will commercialize research from the Max Planck Institutes and other research institutes. The Neuroallianz consortium consists of 12 partners, including Schwarz […]

French biotechnology companies have 73 products in early-stage development and 98 drugs in clinical development, according to France Biotech. Ten drugs are awaiting market approval and four are on the market. Despite economic conditions and a weak IPO market, France Biotech expects French biotech firms to be able to obtain funding through alliances or mergers […]

This month, Sweden announced the largest R&D investment in its history. The Swedish government’s 2009 budget commits SEK 2.4 billion ($364 million) in 2009 to research funding. Such funding will reach SEK 5 billion in 2012. The funding includes the elimination of the value added tax on education. Medicine, technology and the climate will receive […]

India’s Central Drugs Standard Control Organization (CDSCO) is preparing plans to enable foreign drug companies to conduct phase I clinical trials in the country, according to a government official. Currently, only Indian companies can conduct phase 0 and I trials domestically. KPMG estimates that India’s clinical research market was worth $200 million in 2007 and […]

New regulations designed to simplify pesticide residue laws in the EU took effect on September 1. The rules harmonize the maximum residue levels (MRLs) for pesticides and cover approximately 1,100 pesticides used both in the EU and elsewhere. MRLs are listed for 315 agricultural products, including processed products. In addition, a new publicly available database […]

According to South Africa’s “National Survey of Research and Experimental Development: the country’s gross domestic expenditure on R&D totaled ZAR 16,520.6 million ($1.95 billion), 0.95% of GDP, in 2006-2007 for a nominal annual increase of 16.8%. Engineering sciences, natural sciences, and medical and health sciences comprised 20.9%, 20.3% and 15.1% of R&D, respectively. Applied sciences […]

The Chinese government will begin dispersing funds this October for two major research programs that were initially announced two years ago. Although a final figure has yet to be released, observers estimate that $880 million will be allocated for drug discovery research and $440 million will be available for infectious disease research. The projects will […]

An innovation review delivered to the Australian government in August proposes changes in order to boost the country’s R&D spending from 0.55% of GDP to 0.75% of GDP by 2010. Among the proposals are the replacement of the current R&D tax credit, which offers companies an AUD 7.5 cents tax credit per dollar spent on […]